NCT06608355View on ClinicalTrials.gov

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

March 31, 2027

Conditions
Early-onset Parkinson's Disease
Interventions
BIOLOGICAL

Human Dopaminergic Progenitor Cells

Single injection of Human Dopaminergic Progenitor Cells into the putamen of brain.

Trial Locations (1)

430030

RECRUITING

Tongji Hospital Affiliated to Tongji Medical College Hust, Wuhan

All Listed Sponsors
lead

iRegene Therapeutics Co., Ltd.

INDUSTRY